Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-course systemic corticosteroids versus placebo for severe erythema multiforme
2022-000712-59Phase 3Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jan 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in erythema multiforme (EM) comparing Prednisone short-course regimen with Placebo (2 arms). Primary endpoint: Time to success. Started Jan 2023; status: active.
02
Drugs
prednisone
03
Conditions
erythema multiforme (EM)
Beyond the preview
Go deeper on 2022-000712-59.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000712-59.